STOCK TITAN
  1. Home
  2. Sec-filings
  3. GNPX
  4. [8-K] Genprex, Inc. Reports Material Event

Israel grants Genprex (NASDAQ: GNPX) patent for REQORSA lung cancer use

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Genprex, Inc. announced that the Israel Patent Office has granted a patent covering the use of its REQORSA Gene Therapy (quaratusugene ozeplasmid) in combination with PD-1 antibodies for the treatment of cancer. This extends Genprex’s intellectual property around REQORSA beyond prior patents granted in the U.S., Japan, Mexico, Russia, Australia, Chile, China, Singapore and Europe.

REQORSA is initially being developed with approved cancer drugs to treat lung cancer, where preclinical studies have shown it can complement targeted drugs and immunotherapies. The company highlights Israeli public health data showing lung cancer is a leading cause of cancer deaths, underscoring the medical need in that market.

Positive

  • None.

Negative

  • None.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Lung cancer case growth in Israel 33% increase Change over a decade to 2020 in number of cases (not per capita)
New lung cancer cases in Israel 200 new cases per month Incidence reported by Israeli Ministry of Health in 2020
Lung cancer share of cancer mortality in Israel 26% Lung cancer mortality as share of all cancer deaths in 2015
Share of cancer deaths in Israeli men 21.1% Lung cancer share of all cancer deaths among Israeli men in 2021
Share of cancer deaths in Israeli women 11.8% Lung cancer share of all cancer deaths among Israeli women in 2021
Israel lung cancer incidence rank 42 Israel’s global rank by number of new lung cancer cases
Israel lung cancer mortality rank 66 Israel’s global rank by lung cancer mortality
REQORSA Gene Therapy medical
"a patent covering the use of Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination"
PD-1 antibodies medical
"use of Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with PD-1 antibodies for the treatment"
PD-1 antibodies are lab-made proteins that block the PD-1 pathway, a biological “brake” on immune cells, allowing the body's immune system to better recognize and attack cancer cells. Investors watch them because their success in clinical trials, regulatory approval, safety profile and adoption can drive large drug sales or create competitive shifts in biotech portfolios, while trial setbacks or safety concerns can sharply affect company value.
Israel Patent Office regulatory
"announced that the Israel Patent Office (“ILPO”) has granted Genprex a patent covering"
forward-looking statements regulatory
"Statements contained in this on regarding matters that are not historical facts are “forward-looking statements”"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Nasdaq Capital Market financial
"ability to regain and/or maintain compliance with the continued listing requirements of The Nasdaq Capital Market"
The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.
Understanding 8-K Material Events →
false 0001595248 0001595248 2026-04-30 2026-04-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 
   
 
 
FORM 8-K
    
 
 
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
 
April 30, 2026
Date of report (Date of earliest event reported)
 
GENPREX, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
001-38244
90-0772347
(State or other jurisdiction of
incorporation or organization)
(Commission File Number)
(I.R.S. Employer
Identification Number)
     
3300 Bee Cave Road, #650-227, Austin, TX
  
78746
(Address of principal executive offices)
  
(Zip Code)
 
Registrant’s telephone number, including area code: (512) 537-7997
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
  
Trading
Symbol(s)
  
Name of each exchange on which registered
Common Stock, par value $0.001 per share
  
GNPX
  
The Nasdaq Capital Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
Item 8.01 Other Events.
 
On April 30, 2026, Genprex, Inc. (“Genprex” or the “Company”) issued a press release in which it announced that the Israel Patent Office (“ILPO”) has granted Genprex a patent covering the use of Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with PD-1 antibodies for the treatment of cancer. The press release noted that this strategic expansion builds upon the Company’s existing intellectual property in numerous major markets worldwide and underscores the scientific innovation behind REQORSA. The press release further noted that this patent will expand on the previously granted patents for REQORSA in combination with PD-1 antibodies, which have been granted in the U.S., Japan, Mexico, Russia, Australia, Chile, China, Singapore and Europe.  
 
REQORSA is initially being developed in combination with prominent, approved cancer drugs to treat lung cancer. In preclinical studies, REQORSA has been shown to be complementary with targeted drugs and immunotherapies. The Company believes REQORSA’s unique attributes position it to provide potential treatments that improve on these current therapies for patients with lung cancer and possibly other cancers.  The press release noted that according to the Israeli Ministry of Health, in 2020, the number of cases of lung cancer in Israel increased by 33% (not per capita) within a decade, with 200 new cases diagnosed every month. In 2015, the lung cancer mortality rate reached 26% of the mortality rate from all cancers. According to the Israel Cancer Association, in 2021 lung cancer was the number one cancer death cause in Israeli population, responsible for 21.1% of all cancer deaths among Israeli men and 11.8% cancer deaths among Israeli women. Israel is ranked 42 in terms of lung cancer incidence (number of new cases diagnosed) and 66 in lung cancer mortality worldwide.
 
Cautionary Language Concerning Forward-Looking Statements
 
Statements contained in this Current Report on Form 8-K regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex’s reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under “Item 1A – Risk Factors” in Genprex’s Annual Report on Form 10-K for the year ended December 31, 2025.
 
Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex’s ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines; the timing and success of Genprex’s clinical trials and regulatory approvals; the effect of Genprex’s product candidates, alone and in combination with other therapies, on cancer and diabetes; the effects of any strategic research and development prioritization initiatives, and any other strategic alternatives or other efforts that Genprex takes or may take in the future that are aimed at optimizing and re-focusing Genprex’s diabetes, oncology and/or other clinical development programs including prioritization of resources, and the extent to which Genprex is able to implement such efforts and initiatives successfully to achieve the desired and intended results thereof; Genprex’s future growth and financial status, including Genprex’s ability to regain and/or maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex’s commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex’s intellectual property and licenses.
 
These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this filing. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this filing or to reflect the occurrence of unanticipated events, except as required by law.
 
Item 9.01 Financial Statements and Exhibits.
 
(d) Exhibits.
 
Exhibit
Number
 
 Description
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
GENPREX, INC.
  
       
Date: April 30, 2026
By:
/s/ Ryan Confer
  
   
Ryan Confer
  
   
Chief Executive Officer and Chief Financial Officer
(Principal Executive Officer and Principal Financial and Accounting Officer)
  
 
 

Source: View Original Filing on SEC EDGAR

FAQ

What did Genprex (GNPX) announce in its latest 8-K filing?

Genprex announced that the Israel Patent Office granted a patent for using REQORSA Gene Therapy with PD-1 antibodies to treat cancer. This builds on existing patents in major markets and supports the company’s global intellectual property strategy for its oncology platform.

What does the new Israel patent cover for Genprex (GNPX)?

The patent covers the use of REQORSA Gene Therapy (quaratusugene ozeplasmid) in combination with PD-1 antibodies for cancer treatment. This combination approach targets immunotherapy regimens, potentially broadening how REQORSA could be used alongside established cancer drugs.

How does this patent fit into Genprex (GNPX) REQORSA global IP portfolio?

Genprex notes the Israel patent expands previously granted patents for REQORSA with PD-1 antibodies already issued in the U.S., Japan, Mexico, Russia, Australia, Chile, China, Singapore and Europe. Together, these patents support protection for REQORSA combination therapies across numerous major markets.

What cancer indication is Genprex (GNPX) initially targeting with REQORSA?

REQORSA is initially being developed in combination with prominent, approved cancer drugs to treat lung cancer. The company highlights preclinical studies showing REQORSA can complement targeted therapies and immunotherapies, aiming to improve on current treatment options for lung cancer patients.

What lung cancer statistics in Israel did Genprex (GNPX) highlight?

Genprex cited Israeli data showing lung cancer cases rose 33% over a decade by 2020, with about 200 new cases monthly. Lung cancer accounted for 26% of all cancer mortality in 2015, and in 2021 it remained the leading cause of cancer death among Israeli men and a major cause for women.

What forward-looking risks does Genprex (GNPX) emphasize in this disclosure?

Genprex cautions that statements about clinical development, manufacturing, regulatory approvals, commercialization, strategic initiatives, financial status, Nasdaq listing compliance, partnerships and intellectual property are forward-looking. Outcomes may differ materially due to risks discussed in its SEC reports, including risk factors in its latest Form 10-K.

Filing Exhibits & Attachments

4 documents

Other Documents